Silexion Therapeutics Corp (SLXN) Stock Price, Quote & News

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 2 674 3430

Fax: 972 2 643 0982

Website: silexion.com

Address:

The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel

makedatbread88 Dec. 4 at 9:17 PM

$SLXN niceeee ****FOLLOW ME for more winning calls!****

0 · Reply

WallStWireAds Dec. 2 at 1:02 PM

$SLXN https://caplynx.io/6IgQpof

0 · Reply

Stock_Catcher Dec. 2 at 1:00 PM

$SLXN Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

0 · Reply

BioTechHealthX Nov. 27 at 4:49 AM

$SLXN Silexion Therapeutics (SLXN) is emerging as a major player in KRAS-mutated cancer therapies, a market projected to reach $5.8B by 2030. Learn why this clinical-stage biotech is gaining investor attention ahead of its NobleCon21 presentation. https://biotechhealthx.com/biotech-news/silexion-therapeutics-slxn-targets-kras-mutation-market-worth-5-8b-heres-why-investors-are-watching-closely/

0 · Reply

makedatbread88 Nov. 26 at 8:45 PM

$SLXN niceeee ***FOLLOW ME for more winning calls!***

0 · Reply

DylanGFM Nov. 26 at 8:05 PM

$SLXN came up on low volume also...

0 · Reply

ZacksResearch Nov. 26 at 1:38 PM

"$SLXN up 10% — and today’s news explains exactly why traders are piling in. 🔥 Silexion confirmed SIL204 cleared two-species toxicology studies with no systemic organ toxicity, keeping the company on track for its Phase 2/3 pancreatic cancer trial in Q2 2026 and backing what management calls “remarkable potential” in its preclinical package. Regulatory submissions to Israel and Germany are already in motion. " https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-22528&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_22528

0 · Reply

2pumps1dump Nov. 26 at 1:31 PM

$SLXN

0 · Reply

makedatbread88 Nov. 26 at 1:17 PM

$SLXN low floater doing a presentation December 3 Offering at $4 and sitting below that price currently Looks interesting here

0 · Reply

Gated_Lambo Nov. 26 at 1:16 PM

$SLXN $PLTR https://www.rttnews.com/3598838/silexion-completes-toxicology-studies-for-sil204-phase-2-3-pancreatic-cancer-trial-to-begin-in-q2.aspx @MS_Tammy

0 · Reply

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Nov 25, 2025, 9:15 AM EST - 9 days ago

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Nov 12, 2025, 9:00 AM EST - 22 days ago

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 30, 2025, 8:40 AM EDT - 2 months ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Sep 25, 2025, 8:45 AM EDT - 2 months ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Sep 11, 2025, 1:26 PM EDT - 3 months ago

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Sep 11, 2025, 9:17 AM EDT - 3 months ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Sep 11, 2025, 7:00 AM EDT - 3 months ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 4, 2025, 9:25 AM EDT - 3 months ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 2, 2025, 8:45 AM EDT - 3 months ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Aug 12, 2025, 8:00 AM EDT - 4 months ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 PM EDT - 4 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 9:55 AM EDT - 4 months ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 16, 2025, 8:44 AM EDT - 5 months ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 9, 2025, 8:30 AM EDT - 5 months ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

May 22, 2025, 3:46 PM EDT - 7 months ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 21, 2025, 8:45 AM EDT - 7 months ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 13, 2025, 4:45 PM EDT - 7 months ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 23, 2025, 9:20 AM EDT - 8 months ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Mar 28, 2025, 8:30 AM EDT - 8 months ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 21, 2025, 8:30 AM EDT - 9 months ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 18, 2025, 4:29 PM EDT - 9 months ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 17, 2025, 8:15 AM EDT - 9 months ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 5, 2025, 12:05 PM EST - 9 months ago

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Mar 5, 2025, 8:30 AM EST - 9 months ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 3, 2025, 8:30 AM EST - 9 months ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Feb 25, 2025, 8:30 AM EST - 10 months ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Jan 29, 2025, 5:30 PM EST - 11 months ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 9:59 AM EST - 11 months ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 28, 2025, 8:29 AM EST - 11 months ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 16, 2025, 12:08 PM EST - 11 months ago

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Jan 16, 2025, 11:04 AM EST - 11 months ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 8:51 AM EST - 11 months ago

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LUV

Jan 15, 2025, 8:00 PM EST - 11 months ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 4:01 PM EST - 11 months ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 13, 2025, 7:50 AM EST - 11 months ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Dec 17, 2024, 9:36 AM EST - 1 year ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Oct 1, 2024, 6:45 AM EDT - 1 year ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Sep 24, 2024, 9:25 AM EDT - 1 year ago

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 9, 2024, 7:32 AM EDT - 1 year ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

makedatbread88 Dec. 4 at 9:17 PM

$SLXN niceeee ****FOLLOW ME for more winning calls!****

0 · Reply

WallStWireAds Dec. 2 at 1:02 PM

$SLXN https://caplynx.io/6IgQpof

0 · Reply

Stock_Catcher Dec. 2 at 1:00 PM

$SLXN Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

0 · Reply

BioTechHealthX Nov. 27 at 4:49 AM

0 · Reply

makedatbread88 Nov. 26 at 8:45 PM

$SLXN niceeee ***FOLLOW ME for more winning calls!***

0 · Reply

DylanGFM Nov. 26 at 8:05 PM

$SLXN came up on low volume also...

0 · Reply

ZacksResearch Nov. 26 at 1:38 PM

0 · Reply

2pumps1dump Nov. 26 at 1:31 PM

$SLXN

0 · Reply

makedatbread88 Nov. 26 at 1:17 PM

$SLXN low floater doing a presentation December 3 Offering at $4 and sitting below that price currently Looks interesting here

0 · Reply

Gated_Lambo Nov. 26 at 1:16 PM

$SLXN $PLTR https://www.rttnews.com/3598838/silexion-completes-toxicology-studies-for-sil204-phase-2-3-pancreatic-cancer-trial-to-begin-in-q2.aspx @MS_Tammy

0 · Reply

WallStWireAds Nov. 26 at 12:32 PM

$SLXN https://caplynx.io/DBqgm0r

0 · Reply

Gated_Lambo Nov. 26 at 6:08 AM

$SLXN

0 · Reply

topstockalerts Nov. 25 at 4:41 PM

Silexion Therapeutics shares rose Tuesday after the company reported successful completion of toxicology studies for its cancer therapy SIL204, showing no systemic organ toxicity in two species. The positive results keep the biotech on track to begin a Phase 2/3 trial for locally advanced pancreatic cancer in Q2 2026, with regulatory filings underway in Israel and Germany. SIL204, an RNA-silencing therapy targeting mutated KRAS oncogenes, demonstrated strong preclinical activity, including tumor growth inhibition and systemic antitumor effects in pancreatic cancer models. CEO Ilan Hadar said the findings support the company’s planned trial timeline and noted that Silexion has secured its CRO partner and is advancing regulatory submissions. $SLXN

0 · Reply

prismmarketview Nov. 25 at 3:54 PM

(NASDAQ: $SLXN) @SLXNTheraputics completed toxicology studies for SIL204, confirming no systemic organ toxicity and enabling progression toward Phase 2/3 trials in advanced pancreatic cancer set for Q2 2026. https://prismmarketview.com/silexion-advances-sil204-toward-phase-2-3-after-completing-toxicology-studies/

0 · Reply

WallStWireAds Nov. 25 at 3:35 PM

$SLXN https://caplynx.io/71Y0g27

0 · Reply

newbulloh2 Nov. 24 at 9:41 AM

$SLXN seemed like we had some buyers back under a dobbler couple mumfs ago, lets rock her back down shall we!

0 · Reply

topstockalerts Nov. 21 at 1:11 PM

Pre Market Top Gainers $NVVE $MNDR $INDP $SLXN $SMX

1 · Reply

topstockalerts Nov. 21 at 12:40 PM

Pre Market Top Gainers. $NVVE $MNDR $SMX $SLXN $ENLV

0 · Reply

topstockalerts Nov. 21 at 12:05 PM

Pre Market Top Gainers $MNDR $NVVE $SLXN $IVP $EHGO

0 · Reply

topstockalerts Nov. 20 at 11:57 AM

Pre Market Top Gainers PT2 $SLXN $ODD $KLIC $FGL $CRWG

0 · Reply

ZacksResearch Nov. 13 at 1:52 PM

$SLXN narrows its losses by 72% — is this the start of a turnaround? 🔄 The biotech posted a Q3 net loss of $3.3M vs. $11.9M a year ago, after completing a $9.5M public offering 💰. It’s also moving closer to Phase II/III trials for its siRNA cancer candidate SIL-204, with CRO support now locked in for 2026. See the upside Wall Street expects 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-20831&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_20831

0 · Reply

WallStWireAds Nov. 12 at 2:03 PM

$SLXN https://caplynx.io/DZpZHmO

0 · Reply

Market Cap	7.97M
Revenue (ttm)	0.00
Net Income (ttm)	-16.44M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.22

Volume	117,000
Avg Vol	197,364
Day's Range	N/A - N/A
Shares Out	3.13M
Stochastic %K	94%
Beta	-0.06
Analysts	Strong Sell
Price Target	$12.00